iOrganBio, an innovator in intelligent cell manufacturing, has announced the appointment of Lee L. Rubin, Ph.D., to its Scientific Advisory Board. Dr. Rubin is a leading authority in stem cell biology, regenerative medicine, and translational neuroscience, whose research has advanced the understanding of neurodegenerative diseases and contributed to the development of multiple therapeutic candidates. He serves as Co-Director and Principal Faculty of the Harvard Stem Cell Institute and Professor in Harvard’s Department of Stem Cell and Regenerative Biology.
Dr. Rubin’s pioneering work spans blood-brain barrier biology, neural stem cell differentiation, disease modeling using patient-derived induced pluripotent stem cells, and the discovery of therapeutic candidates for disorders including Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and spinal muscular atrophy (SMA). His appointment is expected to expand iOrganBio’s platform in neurological applications, leveraging his extensive academic and entrepreneurial leadership.
iOrganBio’s CellForge platform combines AI prediction, biological sensing, and automated 3D incubation to engineer human cells and organoids with greater precision and consistency. This enables scalable production for disease modeling, drug discovery, and cell therapy development. The platform uses AI and automation to guide cell development and make real-time adjustments aligned with defined biological profiles. At its core is iOrganBio’s functional human CellAtlas, a comprehensive reference built from single-cell and multi-omics data that provides digital blueprints for each cell type.
The company is redefining how human cells are engineered and produced at scale for research and therapeutic applications, including FDA-aligned New Approach Methodologies (NAMs). By applying engineering precision to biology, iOrganBio aims to deliver the accuracy, efficiency, and quality partners need to turn scientific ideas into breakthroughs, accelerating disease modeling, regenerative medicine, and drug development.
For more information, visit iOrgan.Bio or follow on LinkedIn.
